trending Market Intelligence /marketintelligence/en/news-insights/trending/d1xxJiViUT4F_cP6kDsBQg2 content esgSubNav
In This List

PureTech Health acquires remaining stake in Ariya Therapeutics

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


PureTech Health acquires remaining stake in Ariya Therapeutics

PureTech Health PLC acquired the remaining 10% stake in Ariya Therapeutics Inc. and renamed the unit PureTech LYT Inc.

The PureTech LYT unit holds PureTech's four technology platforms, which include immuno-oncology, synthetic lymphatic chemistry, milk exosomes and meningeal lymphatics. The remaining 10% stake was previously held by the co-inventors of these four technology platforms and associated universities and advisers.

As part of the acquisition, the Boston-based, London-listed company will issue 2,126,338 new ordinary shares and will grant options to the co-inventors to purchase 2,147,295 ordinary shares under the PureTech health performance share plan. The shares will be subject to lock-up agreements and will not be tradable until Oct. 1, 2021.